Sanochemia files Scanlux in US

The Austrian public pharmaceutical company, Sanochemia Pharmazeutika AG, whose shares are traded in the Prime Segment of the Frankfurt Stock Exchange under code ISIN AT0000776307, announces the filing of a marketing approval submission for its leading X-ray imaging agent, Scanlux with the U.S. Food and Drug Administration (FDA). The approval process is expected to last at least 12 months. Sanochemia plans to launch Scanlux in the United States by the end of 2008, using a U.S. production partner and a nationwide distribution system.

Significant Boost for Sales Growth through Geographic Expansion

This additional regulatory submission for Scanlux will add further support to Sanochemia’s international market position in the field of X-ray contrast agents. Entering the $2.2 billion U.S. market is of particular importance for Sanochemia because it is generally more profitable than the European market, and also has greater potential for growth. Sanochemia’s forecasts, believed to be slightly conservative, call for sales of $3-5 million within the first few years following launch of Scanlux in the world’s largest pharmaceutical market.

The regulatory process for Scanlux in China has been ongoing since the spring of 2007. Launch is scheduled for Sanochemia’s 2008/09 business year, and will mark a milestone on the road towards market expansion in the entire East Asian region.

Recently, regulatory approval for Scanlux was secured in Italy – one of the most important European markets and the 32th country where market approval has been applied for. First Italian contributions to Scanlux sales are anticipated for the end of this year.

“Our track record of success in the countries where we entered the market shows that this imaging agent, which was developed by Sanochemia, carries the potential for being marketed around the globe,” commented Maximilian Hudl, Executive Director for Marketing and Sales. “Sanochemia Diagnostics will consistently develop its sales network, significantly supporting the organic growth drive of the company, and its contribution to the corporate balance sheet will grow correspondingly.”
Please note: Sanochemia will report its most recent quarterly results (for the period ending on June 30, 2007) on occasion of the Small Cap Conference in Frankfurt/M. on August 27, 2007.

For additional information please contact:
Margarita Hoch Investor Relations Tel.: +43-1-3191456-335 E-mail: m.hoch(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)